SCHEMBL25834182

SCHEMBL25834182

Cc1cc(CNC(=O)NC2CC2)c(F)cc1C#N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 6/20 0.43
PDE4B Q07343 6/20 0.43
PDE4C Q08493 6/20 0.43
PDE4D Q08499 4/20 0.43
HPGD P15428 4/20 0.41
POLB P06746 3/20 0.41
KDM4E B2RXH2 1/20 0.41
TSHR P16473 1/20 0.41
CASP1 P29466 1/20 0.41
HSD17B10 Q99714 1/20 0.41
SMN1; SMN2 Q16637 4/20 0.40
RAB9A P51151 3/20 0.40
MAPT P10636 2/20 0.37
MCHR1 Q99705 2/20 0.37
ALDH1A1 P00352 1/20 0.36
GLA P06280 1/20 0.36
EPHX1 P07099 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
AR P10275 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25836962 0.81 HPGD (0.46) HPGDPOLBTSHRSMN1; SMN2RAB9A
SCHEMBL25836749 0.76 RAB9A (0.53) HPGDPOLBSMN1; SMN2RAB9AMAPT
SCHEMBL12763849 0.70 TRPV4 (0.38) POLBKDM4ETSHRMAPTALDH1A1
SCHEMBL25834549 0.70 P2RX7 (0.52) HPGDEPHX1HTT
SCHEMBL15760957 0.66 KDM1A (0.45) PDE4APDE4BPDE4CPDE4DHPGD
SCHEMBL27423559 0.66 P2RX7 (0.53) EPHX1
SCHEMBL4981117 0.66 ACKR3 (0.54) TSHRRAB9AMCHR1ALDH1A1
SCHEMBL27429577 0.66 TRPV4 (0.34) POLBALDH1A1KMT2A
SCHEMBL6154623 0.65 ROCK2 (0.44) PDE4APDE4BPDE4CPDE4DMEN1
SCHEMBL6154624 0.65 ROCK2 (0.44) PDE4APDE4BPDE4CPDE4DMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208923-A1 SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION JNANA THERAPEUTICS INC. 2024-06-27 US disclosed
WO-2023122267-A2 SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION JNANA THERAPEUTICS INC. (US) 2023-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208923-A1 SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION SLC18A2, SLC6A19, SLC1A1 PDE4A 1999/4885PDE4B 2180/4885PDE4C 2187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.